Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ASPI 
ASP Isotopes Inc. Common Stock (ASPI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ASPI (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 345.11% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 806.08M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 1 | Beta 3.38 | 52 Weeks Range 2.54 - 11.68 | Updated Date 09/13/2025 |
52 Weeks Range 2.54 - 11.68 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-09-03 | When - | Estimate -0.04 | Actual -1.03 |
Profitability
Profit Margin - | Operating Margin (TTM) -998.76% |
Management Effectiveness
Return on Assets (TTM) -21.64% | Return on Equity (TTM) -469.6% |
Valuation
Trailing PE - | Forward PE 54.35 | Enterprise Value 840087628 | Price to Sales(TTM) 175.94 |
Enterprise Value 840087628 | Price to Sales(TTM) 175.94 | ||
Enterprise Value to Revenue 183.36 | Enterprise Value to EBITDA -12.17 | Shares Outstanding 91913104 | Shares Floating 65916405 |
Shares Outstanding 91913104 | Shares Floating 65916405 | ||
Percent Insiders 23.5 | Percent Institutions 45.39 |
Upturn AI SWOT
ASP Isotopes Inc. Common Stock
Company Overview
History and Background
ASP Isotopes Inc. was founded to develop and commercialize isotope enrichment technology for various applications, including nuclear medicine, advanced materials, and other industrial uses. It has evolved through research and development efforts and collaborations to refine its separation technology.
Core Business Areas
- Isotope Enrichment: Specializes in the enrichment of isotopes for medical, industrial, and research applications.
- Separation Technology: Develops and utilizes advanced separation technologies to produce high-purity isotopes.
- Product Development: Focuses on developing and commercializing isotopes for radiopharmaceuticals and other industrial markets
Leadership and Structure
Information on leadership and structure is limited. Public sources reveal management roles but detailed organizational charts are less accessible. Generally, it has a board of directors overseeing executive management.
Top Products and Market Share
Key Offerings
- Enriched Molybdenum-99 (Mo-99): Used in medical imaging for diagnostic procedures. Market share data is variable and depends on production capacity and competition. Competitors include global isotope producers like Curium, NorthStar Medical Radioisotopes, and ANSTO. Revenue figures are confidential.
- Other Enriched Isotopes: Includes isotopes for research and industrial applications, market share depends on specific isotope and customer needs. Details unavailable.
Market Dynamics
Industry Overview
The isotope enrichment market is driven by demand from healthcare, industrial, and research sectors. It is characterized by high barriers to entry due to technological complexity and regulatory requirements.
Positioning
ASP Isotopes aims to be a significant player in the isotope enrichment market through its proprietary technology, focusing on high-value applications like Mo-99 production.
Total Addressable Market (TAM)
The TAM for the global isotope market is estimated to be in the billions of dollars. ASP Isotopes is positioned to capture a portion of this market focusing on enriched isotopes for various industrial markets.
Upturn SWOT Analysis
Strengths
- Proprietary isotope enrichment technology
- Potential for high-purity isotope production
- Focus on high-value applications
Weaknesses
- Limited commercial scale production
- Reliance on funding for expansion
- Competitive landscape with established players
Opportunities
- Growing demand for medical isotopes
- Expansion into new isotope applications
- Strategic partnerships with industry players
Threats
- Competition from established isotope producers
- Regulatory hurdles
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Curium (Private)
- NorthStar Medical Radioisotopes (Private)
- ANSTO (Australia Government)
Competitive Landscape
ASP Isotopes faces competition from established global players with larger production capacities. ASP Isotopes has a small market share. However, ASP Isotopes aims to differentiate itself through its proprietary technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to quantify due to the limited information available.
Future Projections: Future growth projections are not available from analysts.
Recent Initiatives: Company press releases mention strategic initiatives aimed at commercializing isotope production.
Summary
ASP Isotopes is a developing company in the isotope enrichment market with proprietary technology. While it faces strong competition from established players, its focus on high-value applications and strategic partnerships present opportunities for growth. A key challenge is scaling up production and securing funding. Overall, it's a potentially promising venture but requires diligent execution and management of risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Industry Reports
- Limited Financial Filings
Disclaimers:
Data is based on publicly available information, which may be limited or incomplete. Market share estimates are approximate. Financial performance analysis is constrained by lack of detailed financial statements. This analysis is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ASP Isotopes Inc. Common Stock
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2022-11-10 | President, CEO & Executive Chairman Mr. Paul Elliot Mann C.F.A. | ||
Sector Basic Materials | Industry Chemicals | Full time employees 136 | Website https://aspisotopes.com |
Full time employees 136 | Website https://aspisotopes.com | ||
ASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs. The company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-67/68, Nickel-64, and Xenon 129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. ASP Isotopes Inc. was incorporated in 2021 and is based in Washington, District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.